Israeli telehealth firm Tyto Care announced that it was expanding the production of its remote medical testing devices to meet the demand of healthcare organizations as they battle the coronavirus pandemic.
Tyto Care said hospitals and health organizations in the US, Europe and Israel are expanding their use of Tyto’s telehealth solutions to remotely examine and diagnose quarantined and isolated patients. The company’s handheld devices that examine the heart, lungs, skin, ears, throat and abdomen, as well as measure body temperature, provide health professionals with the clinical data required to make informed treatment decisions while minimizing physical contact.
Tyto’s platforms are already being used at Israeli hospitals including the Sheba Medical Center where over 30 Israelis who have tested positive for COVID-19 are hospitalized in a special facility.
“The fight against the COVID-19 pandemic is strengthening each day and as the virus continues to spread, we are focusing our efforts where we can make the most impact – easing the burden on healthcare providers serving quarantined and isolated patients,” said Dedi Gilad, Tyto Care CEO and co-founder.
“Tyto Care is uniquely suited to provide the remote exam and diagnostic capabilities required to aid affected populations at scale, fully realizing telehealth’s potential during this crisis. It’s my hope that this pandemic passes quickly and that we can help flatten the curve,” he added.
Gilad co-founded Tyto Care alongside Ofer Tzadik in 2012, after spending many days and nights in emergency care as a parent of young children.
Tyto Care’s TytoHome platform for home use was named as one of TIME Magazine’s top inventions for 2019 in the “health category.” The device allows users to perform comprehensive medical exams and send the information to a primary care provider. The device, at $299, was recently made available to purchase at over 300 Best Buy locations across the US. It’s also available online.
Tyto Care also developed TytoPro for professionals and TytoClinic for remote point-of-care testing. The company has FDA clearance and launched its products in the US in 2017. It also has a CE mark for Europe and gained Health Canada approval in 2018.
Tyto has raised over $50 million in funding to date.